BeiGene, Ltd.
BGNE
Classifica tra le azioni
#1179
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$184.00
Ultima sincronizzazione: 2025-01-02
Capitalizzazione di mercato
$19.28B
Variazione (1 giorno)
-0.38%
Variazione (1 anno)
0.00%
Paese
US
Scambia BeiGene, Ltd. (BGNE)
Categoria
Healthcare
Ricavi di BeiGene, Ltd. (BGNE)
Ricavi nel Jun 2026 TTM: $6.13B
Secondo gli ultimi rapporti finanziari di BeiGene, Ltd., i ricavi attuali dell'azienda (TTM) sono pari a $6.13B. Nel 2023, l'azienda ha registrato ricavi di $2.46B un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $1.42B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per BeiGene, Ltd. da 2013 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $6.13B | 60.85% |
| 2024 | $3.81B | 54.96% |
| 2023 | $2.46B | 73.65% |
| 2022 | $1.42B | 20.37% |
| 2021 | $1.18B | 280.83% |
| 2020 | $308.87M | -27.87% |
| 2019 | $428.21M | 116.03% |
| 2018 | $198.22M | -16.85% |
| 2017 | $238.39M | 22,179.16% |
| 2016 | $1.07M | -87.86% |
| 2015 | $8.82M | -32.37% |
| 2014 | $13.04M | 16.93% |
| 2013 | $11.15M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 105.98% |
US
|
|
| $2.23B | -63.65% |
US
|
|
| $15.74B | 156.88% |
AU
|
|
| $6.02B | -1.76% |
NL
|
|
| - | - |
CH
|
